What we're reading, September 22, 2016: a new bill would cap out-of-pocket costs for Medicare beneficiaries; world leaders agreed to a global effort to curb the spread of superbugs; and Mark Zuckerberg and Priscilla Chan, MD, will donate $3 billion over 10 years to cure disease.
A new bill would cap out-of-pocket costs for seniors in traditional Medicare. According to Morning Consult, the bill is unlikely to pass in a Republican-controlled Congress, but could be a glimpse of the future of Democrats take back control after this election. The Medicare Affordability and Enrollment Act, introduced by Senator Ron Wyden, D-Oregon, would cap out-of-pocket spending for Medicare at $5500, and also expand eligibility among low-income seniors.
The first global effort to stop the spread of drug resistance bacteria is beginning. World leaders have agreed on steps to curb the spread of so-called “superbugs” that are becoming immune to many medicines, reported The New York Times. However, the agreement is nonbinding and has required no commitments to specific targets. Approximately 700,000 people die every year from drug-resistant infections.
A $3 billion donation over 10 years from Mark Zuckerberg and Priscilla Chan, MD, will be used to try to cure, prevent, or manage all diseases by the end of the century. The couple’s philanthropic organization will bring together scientists and engineers with the goal that people get sick less often and are able to better manage diseases, according to STAT. Part of the effort includes $600 million to create a cooperative involving the University of California, San Francisco, the University of California, Berkeley, and Stanford University.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More